ADAM8 has been implicated in the increase of cellular motility in pancreatic cancer (Valkovskaya et al., 2007), in breast cancer (Das et al., 2016), in primary brain cancer (Wildeboer et al., 2006) and prostate cancer (Fritzsche et al., 2006). Here, ADAM8 is linked to pancreatic neoplasm.